Literature DB >> 14745718

Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung.

Reda S Saad1, Yulin L Liu, Helen Han, Rodney J Landreneau, Jan F Silverman.   

Abstract

Thyroid transcription factor 1 (TTF-1) is a diagnostic immunohistochemical marker for primary pulmonary neoplasms, but its utility as a prognostic marker is not well established. Surgical specimens from 100 cases of pulmonary adenocarcinoma were retrieved from the hospital computer system, including 50 cases of conventional adenocarcinoma (CA) and 50 cases of bronchioloalveolar adenocarcinoma (BAC) (32 nonmucinous type and 18 mucinous type). Representative sections were immunostained for TTF-1. Positive immunohistochemical study was correlated with other prognostic parameters. In the CA group, strong or moderate TTF-1 expression was seen in 30 of 50 (60%) patients and was associated with significantly better survival compared with those patients having weak staining (7 cases; 14%) or negative staining (13 cases; 26%) (P <0.01; log-rank test). Spearman and Pearson's correlation showed no significant correlation between TTF-1 expression and tumor grade, size, recurrence, or vascular invasion; therefore, TTF-1 was considered an independent predictor of survival. In the BAC group, TTF-1 was strongly expressed in 34 of 50 cases (68%) and was negative in 16 of 50 cases (32%), including 14 mucinous BACs. Although TTF-1 immunoreactivity was not statistically associated with good survival in BAC patients, those patients with strong immunohistochemical expression showed a trend toward longer survival. Our results indicate that TTF-1 positivity is an independent predictor of better survival, especially in patients with CA. Mucinous and nonmucinous BACs exhibit disparate staining patterns with TTF-1, with nonmucinous BAC demonstrating greater positivity. Although nonmucinous BAC patients showing strong positive staining had longer survival, the difference was not statistically significant, which is probably related to the overall good survival of patients with early-stage BAC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14745718     DOI: 10.1016/j.humpath.2003.08.011

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  22 in total

1.  Downregulation of EMX2 is associated with clinical outcomes in lung adenocarcinoma patients.

Authors:  Junichi Okamoto; Johannes R Kratz; Tomomi Hirata; Iwao Mikami; Dan Raz; Mark Segal; Zhao Chen; Hai-Meng Zhou; Patrick Pham; Hui Li; Adam Yagui-Beltran; Adam Beltran; M Roshni Ray; Kiyoshi Koizumi; Kazuo Shimizu; David Jablons; Biao He
Journal:  Clin Lung Cancer       Date:  2011-04-24       Impact factor: 4.785

2.  Bronchioloalveolar differentiation in lung adenocarcinomas.

Authors:  Nevena Dukić; Božana Babić; Zivka Eri; Dragana Zec; Aleksandra Lovrenski; Violeta Kolarov
Journal:  Bosn J Basic Med Sci       Date:  2011-11       Impact factor: 3.363

3.  The expression of TTF-1 and Napsin A in early-stage lung adenocarcinoma correlates with the results of surgical treatment.

Authors:  Yunfan Ma; Mengying Fan; Liang Dai; Xiaozheng Kang; Yiqiang Liu; Yu Sun; Wanpu Yan; Zhen Liang; Hongchao Xiong; Keneng Chen
Journal:  Tumour Biol       Date:  2015-05-16

4.  Prognostic model of stage II non-small cell lung cancer by a discriminant analysis of the immunohistochemical protein expression.

Authors:  Takayuki Kohri; Masayuki Sugano; Osamu Kawashima; Ryusei Saito; Shinji Sakurai; Takaaki Sano; Takashi Nakajima
Journal:  Surg Today       Date:  2006-12-25       Impact factor: 2.549

5.  Inverse correlation between galectin-4 and TTF-1 in lung adenocarcinoma.

Authors:  Kieko Hara; Tsuyoshi Saito; Takuo Hayashi; Keiko Mitani; Kazuya Takamochi; Shiaki Oh; Kenji Suzuki; Takashi Yao
Journal:  Virchows Arch       Date:  2017-07-19       Impact factor: 4.064

6.  Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma.

Authors:  Kyuichi Kadota; Jun-Ichi Nitadori; Inderpal S Sarkaria; Camelia S Sima; Xiaoyu Jia; Akihiko Yoshizawa; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  Cancer       Date:  2012-10-23       Impact factor: 6.860

7.  Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung.

Authors:  J Matthew McDonald; Christopher E Pelloski; Alicia Ledoux; Menghong Sun; Gabriela Raso; Ritsuko Komaki; Ignacio I Wistuba; B Nebiyou Bekele; Ken Aldape
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

Review 8.  Nkx2-1: a novel tumor biomarker of lung cancer.

Authors:  Li Yang; Min Lin; Wen-jing Ruan; Liang-liang Dong; En-guo Chen; Xiao-hong Wu; Ke-jing Ying
Journal:  J Zhejiang Univ Sci B       Date:  2012-11       Impact factor: 3.066

9.  EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance.

Authors:  Yongjie Wei; Zhongju Zou; Nils Becker; Matthew Anderson; Rhea Sumpter; Guanghua Xiao; Lisa Kinch; Prasad Koduru; Christhunesa S Christudass; Robert W Veltri; Nick V Grishin; Michael Peyton; John Minna; Govind Bhagat; Beth Levine
Journal:  Cell       Date:  2013-09-12       Impact factor: 41.582

10.  Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung.

Authors:  F Barlési; D Pinot; A Legoffic; C Doddoli; B Chetaille; J-P Torre; P Astoul
Journal:  Br J Cancer       Date:  2005-08-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.